Setup, so nobody has to ask: a 30G needle · 2 mg/mL.
I have worked this out and I would like someone to find the error, because I suspect there is one.
My working so far, for the record, is below, and I am fairly sure the error is in the unit conversion rather than the algebra.
Is my approach right even if my number is wrong?
At 2 mg/mL every microlitre left behind is 2 µg, so a 50 µL hub costs 0.1 mg per draw and a 5 µL fixed-needle barrel costs 0.01 mg. Multiply by the draws, not by the doses: ten draws through a 50 µL dead space is 1 mg gone, which at 2 mg/mL is 0.5 mL of solution you paid for and never administered. Against a 2 mg dose that 50 µL is 5 per cent; against a 0.25 mg dose it is 40 per cent, which is why the loss matters most at exactly the doses where you can least afford it. a 30G needle has a bore, a hub and a length, and the hub dominates: a fixed-needle insulin barrel has almost none, a luer connection has a measurable one before the needle even starts.
To be exact about it, a fixed-needle insulin syringe holds roughly 3 to 5 µL dead space and costs the same as a luer-lock syringe with 35 to 100 µL dead space.
Draws available = 2000 / 102 = 19.6, so 19 full draws. Delivered peptide = 19 x 0.5 mg = 9.5 mg. Lost to dead space = 19 x 2 µL = 38 µL x 0.005 = 0.19 mg. Yield = 95 per cent.
| Appearance | Interpretation | Action |
|---|---|---|
| Intact opaque puck, proud of base | Cycle ran correctly | Proceed |
| Slumped to one side | Shipped before fully dry, or vibration | Usually usable; note it |
| Glassy translucent film | Collapse above glass transition | Test before use |
| Melt-back ring at stopper | Thermal excursion in transit | Test before use |
| No visible cake at all | Very low fill, or nothing there | Weigh it; query the supplier |
Mechanically, the luer cone of the syringe plus the needle's own plastic hub accounts for the vast majority of the dead space.
Published inter-laboratory comparisons of dead-space measurements on identical syringes show good agreement, suggesting the numbers are reliable.
The switch nearly doubles your vial, which is better than most other optimisations combined.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemBefore anything else: understand that dead space is a property of the syringe architecture, not of the needle gauge.
The complete rule: fix the syringe architecture first, and then the reconstitution volume becomes a free choice you can make on stability grounds rather than on economics.
The part that matters: configuration A — 1 mL luer-lock plus detachable needle, dead space 84 µL: each draw removes 100 + 84 = 184 µL. Draws available from 2,000 µL = 2000 / 184 = 10.87, so 10 full draws.
Syringe residual volume has been measured properly, mainly in the infection-control literature, with a median residual of about 84 µL for a conventional 1 mL syringe with a detachable needle and roughly 2 µL for a fixed-needle low-dead-space design.
One qualification: the dead space does not affect the dose accuracy if the hub was full of solution at the start of the draw.
If cost matters, this is the first thing to change, not the last.
In practice, dead space is irreducible with a high-dead-space syringe, which is why the hardware matters more than any technique.
At 5 mg/mL that is 15 to 25 µg lost per draw on the insulin syringe and 175 to 500 µg on the luer-lock — which over ten draws is the difference between losing a rounding error and losing half a milligram.
The underlying point is that configuration B — 0.5 mL fixed-needle U-100 insulin syringe, dead space 2 µL: volume removed per draw = 100 + 2 = 102 µL.
The caveat is that dead space is a yield loss and not a dose-accuracy loss, so the person feeling this loss most is the person with the most total draws.
Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.
Mechanically, dead space is the volume trapped in the syringe hub and needle after the plunger bottoms out, and it is the reason your 10 mg vial yields only 9.5 mg of usable draws.
Low-dead-space syringe designs either have the needle bonded directly to the barrel — a fixed-needle syringe, which is the cheapest route — or add a moulded projection on the plunger tip that fills the luer cone.
The World Health Organisation guidance on injection equipment adopted the same high-versus-low dead-space distinction, using a low-dead-space threshold in the low single-digit microlitres.
The limitation is that even with perfect technique, some loss is irreducible unless you switch to a low-dead-space syringe.
Write the arithmetic on the vial label. It costs nothing and it removes the step where you reconstruct it from memory at an inconvenient moment.
edited 15 Feb 2025 by ekaterina_volk — corrected a unit error in the worked example
Start from the worked arithmetic: a 10 mg vial reconstituted with 2 mL gives 5 mg/mL. One hundred microliter draws are 0.5 mg each. At 84 µL dead space per draw, half your vial disappears into the hub.
The needle lumen volume is under a microlitre in a typical fine-gauge configuration, so the needle is not the problem.
Worth noting: draw size matters enormously — the smaller your draws, the more the syringe architecture matters.
The practical summary: fine gauge, gentle swirl, diluent down the wall, room temperature before drawing, and check the syringe scale against the barrel rather than against your assumption.
edited 3 Mar 2025 by Dr_Yusuf_Adeyemi — added the citation requested in comments
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.